Adolfo F.
- Country
- Italy
- Department
- 4105:U.O.C. di Oncologia Medica
Research Overview
- Phase II Multicenter Trial of Adagrasib in KRASG12C-Mutant NSCLC Patients Aged ≥70 or with ECOG PS=2
- ETOP 23-22 RAISE: A single-arm phase II study of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.
- Phase II Study of Neoadjuvant Durvalumab and Platinum-Based Chemotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 41 of 176 partner sites.
Specializations
Lung Cancer Research
Specialized in investigating innovative treatments for non-small cell lung cancer (NSCLC), with particular focus on targeted therapies for patients with specific genetic mutations including ALK-rearrangement and KRASG12C mutations.
- Advanced NSCLC Treatment Protocols
- Genetic Mutation-Targeted Therapies
- Combination Treatment Approaches
Additional expertise in extensive-disease small cell lung cancer (ED-SCLC) treatment strategies involving immunotherapy combinations.
Gynecologic Oncology
Focused on developing treatment strategies for recurrent ovarian cancer, particularly investigating combination therapies using pegylated liposomal doxorubicin and innovative therapeutic agents.
- Ovarian Cancer Recurrence Management
- Novel Drug Combinations
- Treatment Optimization Strategies
Expertise in managing platinum-sensitive and platinum-resistant disease cases.
Breast Cancer Studies
Specializes in research concerning triple negative breast cancer, with emphasis on developing adjuvant treatment protocols using immunotherapy approaches.
- High-risk TNBC Management
- Immunotherapy Applications
- Adjuvant Treatment Strategies
Focus on curative treatment approaches combining surgery and systemic therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.